Krilogy Financial LLC Makes New Investment in AstraZeneca PLC $AZNCF

Krilogy Financial LLC purchased a new position in shares of AstraZeneca PLC (OTCMKTS:AZNCF) in the first quarter, HoldingsChannel reports. The fund purchased 3,341 shares of the company’s stock, valued at approximately $670,000.

A number of other institutional investors have also modified their holdings of AZNCF. First City Capital Management Inc. acquired a new stake in AstraZeneca during the first quarter worth approximately $719,000. Town & Country Bank & Trust CO dba First Bankers Trust CO acquired a new position in AstraZeneca in the 1st quarter valued at $1,351,000. Monetary Management Group Inc. acquired a new position in AstraZeneca in the 4th quarter valued at $1,097,000. Seven Mile Advisory purchased a new position in shares of AstraZeneca during the 4th quarter worth $738,000. Finally, L & S Advisors Inc purchased a new position in shares of AstraZeneca during the 4th quarter worth $14,863,000. Institutional investors and hedge funds own 40.87% of the company’s stock.

AstraZeneca Stock Performance

AZNCF stock opened at $187.10 on Friday. AstraZeneca PLC has a 52-week low of $122.26 and a 52-week high of $195.00. The stock’s fifty day simple moving average is $187.10 and its 200-day simple moving average is $186.25.

AstraZeneca Company Profile

AstraZeneca (OTCMKTS:AZNCF) is a global biopharmaceutical company that focuses on the discovery, development, manufacturing and commercialization of prescription medicines. The company’s research and development efforts are concentrated in three main therapeutic areas: oncology; cardiovascular, renal and metabolism; and respiratory, inflammation and autoimmunity. AstraZeneca’s product portfolio includes targeted therapies for lung and breast cancers, novel agents for heart failure and chronic kidney disease, and inhaled treatments for asthma and chronic obstructive pulmonary disease.

The company was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group, creating one of the world’s largest pharmaceutical firms.